Please do not leave this page until complete. This can take a few moments.
The Food and Drug Administration has designated a BioXcel Therapeutics drug a “breakthrough therapy” for dementia-related agitation, a label that has the potential to speed up the regulatory review process.
The FDA reserves the designation for potential medicines that treat a serious or life threatening condition and offer a substantial improvement over existing treatments.
In addition to an expedited review timeline, companies developing breakthrough drugs qualify for more intensive guidance and more frequent interactions with the FDA.
BioXcel said the FDA based its decision on positive topline data from a recent Phase 1b/2 clinical trial showing statistically significant reductions in agitation in patients two hours after taking the drug.
CEO Vimal Mehta said it “further underscores the significant unmet need for a new treatment for this underserved patient population.”
The drug, BXCL501, is a thin-film formulation of an older drug known as “Dex” (dexmedetomidine). It tastes minty and dissolves in the mouth, similar to a mouthwash strip.
Meanwhile last week, BioXcel said it filed its first new drug application (NDA) with the FDA for approval of the drug to treat agitation in patients with schizophrenia and bipolar disorder.
The FDA has 60 days to determine whether to file or reject the NDA. If accepted, the drug would be on track for FDA approval by early 2022.
Contact Natalie Missakian at news@newhavenbiz.com
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments